Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Related Publications
Trial Contact Information
Registry Information

Alternate Title

Collecting Tumor Samples From Patients With Gynecological Tumors

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
No phase specified	Tissue collection/Repository	Active	Not specified	NCI	GOG-0136 NCT00897442

Special Category: NIH Clinical Center trial

Objectives

1. Collect gynecological tumor specimens and blood from patients at GOG institutions.
2. Provide a repository for long-term storage of these specimens.

Entry Criteria

Disease Characteristics:

• Any of the following:
  • Patients who have had gynecologic tissue removed during surgery to diagnosis, treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, meeting at least one of the following criteria:
    • Group A: Women who underwent surgery, were diagnosed with a primary gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and have primary tumor, normal tissue, and blood available for submission for this protocol
      • Patients with ovarian cancer including all stages, grades, and common epithelial cell types
        • Invasive cancers and serous and mucinous borderline tumors of low malignant potential are allowed
        • At least 1 gram of frozen primary tumor tissue must be submitted for this protocol for patients with FIGO stage III or IV epithelial ovarian cancer
      • Patients with an invasive malignancy of the cervix or uterine corpus including all stages, grades, and common cell types
      • Patients with squamous cell carcinoma of the vulva
    • Group B: Women who underwent surgery and were diagnosed with a rare gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor arising in endometriosis, and have tumor tissue available for submission for this protocol
      • Patients with a rare gynecologic malignancy of the ovary including malignant germ cell tumors; sex cord-stromal tumors; malignant mixed mesodermal tumors; clear cell, mucinous, small cell, or transitional cell carcinomas; malignant Brenner tumors; or borderline tumors of low malignant potential (except serous and mucinous)
      • Patients with a rare gynecologic malignancy of the peritoneum, including primary peritoneal cancer or mesothelioma
      • Patients with carcinoma of the fallopian tube
      • Patients with a rare gynecologic malignancy of the cervix including verrucous, small cell, clear cell, serous, or adenoid cystic carcinomas; carcinoid tumors; malignant mixed mesodermal tumors; or leiomyosarcoma
      • Patients with a rare gynecologic malignancy of the uterine corpus including leiomyosarcoma; malignant mixed mesodermal tumors; endometrial stromal sarcomas; smooth muscle tumors of unknown malignant potential; or clear cell or small cell carcinomas
      • Patients with a rare gynecologic malignancy of the vagina including verrucous or clear cell carcinomas; melanoma; embryonal rhabdomyosarcoma; or endodermal sinus tumor
      • Patients with a rare gynecologic malignancy of the vulva including verrucous carcinoma; melanoma; aggressive angiomyxoma; sarcoma; malignant Paget’s disease; or Bartholin gland carcinoma
      • Patients with a gestational trophoblastic tumor
      • Patients with a tumor arising in endometriosis
    • Group C: Women who underwent prophylactic oophorectomy and have at least 1 gram of ovarian tissue and blood available for submission for this protocol
    • Group D: Women who underwent surgery to monitor or treat a persistent or recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent tumor, normal tissue, and blood available for submission for this protocol
• Concurrent primary cancers are allowed
• No benign cystic tumors of the ovary, including cystic epithelial tumors and mature cystic teratomas

Prior/Concurrent Therapy:

Chemotherapy:

• Prior cytotoxic chemotherapy allowed

Endocrine therapy:

• Prior hormonal therapy allowed

Radiotherapy:

• Prior radiotherapy allowed

Surgery:

• Prior surgery allowed
• No more than 6 weeks after prior surgery

Patient Characteristics:

Not specified

Expected Enrollment

Not specified

Outcomes

Collection of gynecological tumor specimens and serum from patients at GOG institutions
Create a repository for long-term storage of these specimens

Outline

Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.

Jewell EL, Darcy KM, Hutson A, et al.: Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol : , 2009.[PUBMED Abstract]

He X, Pool M, Darcy KM, et al.: Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene 26 (34): 4961-8, 2007.[PUBMED Abstract]

Secord AA, Darcy KM, Hutson A, et al.: Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 106 (1): 221-32, 2007.[PUBMED Abstract]

Singh M, Zaino RJ, Filiaci VJ, et al.: Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106 (2): 325-33, 2007.[PUBMED Abstract]

Thrall M, Gallion HH, Kryscio R, et al.: BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 16 (Suppl 1): 166-71, 2006 Jan-Feb.[PUBMED Abstract]

Chatterjee M, Mohapatra S, Ionan A, et al.: Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66 (2): 1181-90, 2006.[PUBMED Abstract]

Connor JP, Felder M, Hank J, et al.: Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 27 (3): 211-9, 2004 May-Jun.[PUBMED Abstract]

Depasquale S, Lambert-Messerlian G, Quddus MR, et al.: Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. Int J Gynecol Cancer 12 (5): 443-7, 2002 Sep-Oct.[PUBMED Abstract]

Hendrix ND, Wu R, Kuick R, et al.: Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66 (3): 1354-62, 2006.[PUBMED Abstract]

Matei D, Emerson RE, Lai YC, et al.: Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25 (14): 2060-9, 2006.[PUBMED Abstract]

Shi W, Hemminki A, Bartlett JS: Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol 103 (3): 1054-62, 2006.[PUBMED Abstract]

Waggoner SE, Darcy KM, Fuhrman B, et al.: Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol 103 (3): 853-8, 2006.[PUBMED Abstract]

Baron AT, Boardman CH, Lafky JM, et al.: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 (2): 306-18, 2005.[PUBMED Abstract]

Chamorro MN, Schwartz DR, Vonica A, et al.: FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development. EMBO J 24 (1): 73-84, 2005.[PUBMED Abstract]

Garcia AA, Blessing JA, Lenz HJ, et al.: Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol 96 (3): 810-7, 2005.[PUBMED Abstract]

Gorelik E, Landsittel DP, Marrangoni AM, et al.: Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 (4): 981-7, 2005.[PUBMED Abstract]

Kozak KR, Su F, Whitelegge JP, et al.: Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 (17): 4589-96, 2005.[PUBMED Abstract]

Parker N, Turk MJ, Westrick E, et al.: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338 (2): 284-93, 2005.[PUBMED Abstract]

Schilder RJ, Sill MW, Chen X, et al.: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11 (15): 5539-48, 2005.[PUBMED Abstract]

Shedden KA, Kshirsagar MP, Schwartz DR, et al.: Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 11 (6): 2123-31, 2005.[PUBMED Abstract]

Shedden K, Chen W, Kuick R, et al.: Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics 6: 26, 2005.[PUBMED Abstract]

Wilcox CB, Baysal BE, Gallion HH, et al.: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159 (2): 114-22, 2005.[PUBMED Abstract]

Balch C, Huang TH, Brown R, et al.: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191 (5): 1552-72, 2004.[PUBMED Abstract]

Baysal BE, DeLoia JA, Willett-Brozick JE, et al.: Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 95 (1): 62-9, 2004.[PUBMED Abstract]

Berry NB, Cho YM, Harrington MA, et al.: Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 92 (3): 896-904, 2004.[PUBMED Abstract]

Burger RA, Darcy KM, DiSaia PJ, et al.: Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer 101 (1): 106-15, 2004.[PUBMED Abstract]

Havrilesky LJ, Alvarez AA, Whitaker R, et al.: Loss of expression of the P16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking P53 mutations. [Abstract] Society of Gynecologic Oncologists 2004 Annual Meeting on Women's Cancer, 7-11 February 2004, San Diego, California. A-814, 2004.

He X, Ee PL, Coon JS, et al.: Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10 (14): 4652-60, 2004.[PUBMED Abstract]

Matei D, Chang DD, Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10 (2): 681-90, 2004.[PUBMED Abstract]

Baron AT, Cora EM, Lafky JM, et al.: Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12 (2): 103-13, 2003.[PUBMED Abstract]

Cvetković D, Williams SJ, Hamilton TC: Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin Cancer Res 9 (3): 1013-20, 2003.[PUBMED Abstract]

Farley J, Smith LM, Darcy KM, et al.: Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 63 (6): 1235-41, 2003.[PUBMED Abstract]

Freitas S, Moore DH, Michael H, et al.: Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 9 (13): 4689-94, 2003.[PUBMED Abstract]

Havrilesky L, Darcy M, Hamdan H, et al.: Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21 (20): 3814-25, 2003.[PUBMED Abstract]

Jones MB, Michener CM, Blanchette JO, et al.: The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. Clin Cancer Res 9 (1): 44-51, 2003.[PUBMED Abstract]

Kozak KR, Amneus MW, Pusey SM, et al.: Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 100 (21): 12343-8, 2003.[PUBMED Abstract]

Lucito R, Healy J, Alexander J, et al.: Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 13 (10): 2291-305, 2003.[PUBMED Abstract]

Mu D, Chen L, Zhang X, et al.: Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3 (3): 297-302, 2003.[PUBMED Abstract]

Nephew KP, Huang TH: Epigenetic gene silencing in cancer initiation and progression. Cancer Lett 190 (2): 125-33, 2003.[PUBMED Abstract]

Nishizuka S, Chen ST, Gwadry FG, et al.: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63 (17): 5243-50, 2003.[PUBMED Abstract]

Rangel LB, Agarwal R, D'Souza T, et al.: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9 (7): 2567-75, 2003.[PUBMED Abstract]

Rangel LB, Sherman-Baust CA, Wernyj RP, et al.: Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene 22 (46): 7225-32, 2003.[PUBMED Abstract]

Reed E, Yu JJ, Davies A, et al.: Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 9 (14): 5299-305, 2003.[PUBMED Abstract]

Schwartz DR, Wu R, Kardia SL, et al.: Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63 (11): 2913-22, 2003.[PUBMED Abstract]

Shedden KA, Taylor JM, Giordano TJ, et al.: Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 163 (5): 1985-95, 2003.[PUBMED Abstract]

Shi H, Wei SH, Leu YW, et al.: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 63 (9): 2164-71, 2003.[PUBMED Abstract]

Shi W, Bartlett JS: RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 7 (4): 515-25, 2003.[PUBMED Abstract]

Whitcomb BP, Mutch DG, Herzog TJ, et al.: Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9 (6): 2277-87, 2003.[PUBMED Abstract]

Wu R, Lin L, Beer DG, et al.: Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol 162 (5): 1603-10, 2003.[PUBMED Abstract]

Zhang L, Yang N, Conejo-Garcia JR, et al.: Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 9 (1): 264-72, 2003.[PUBMED Abstract]

Zhang L, Yang N, Katsaros D, et al.: The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 63 (14): 4225-31, 2003.[PUBMED Abstract]

Kolligs FT, Nieman MT, Winer I, et al.: ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 1 (2): 145-55, 2002.[PUBMED Abstract]

Leung JY, Kolligs FT, Wu R, et al.: Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 277 (24): 21657-65, 2002.[PUBMED Abstract]

Maihle NJ, Baron AT, Barrette BA, et al.: EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107: 247-58, 2002.[PUBMED Abstract]

Okamoto A, Woodworth CD, Yen K, et al.: Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol Rep 6 (2): 269-76, 1999 Mar-Apr.[PUBMED Abstract]

Perlman EJ, Hu J, Ho D, et al.: Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization. J Pediatr Hematol Oncol 22 (2): 100-5, 2000 Mar-Apr.[PUBMED Abstract]

Reedy M, Gallion H, Fowler JM, et al.: Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 85 (2): 255-9, 2002.[PUBMED Abstract]

Roberts D, Williams SJ, Cvetkovic D, et al.: Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol 21 (1): 11-9, 2002.[PUBMED Abstract]

Sawiris GP, Sherman-Baust CA, Becker KG, et al.: Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 62 (10): 2923-8, 2002.[PUBMED Abstract]

Schwartz DR, Kardia SL, Shedden KA, et al.: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62 (16): 4722-9, 2002.[PUBMED Abstract]

Talora C, Sgroi DC, Crum CP, et al.: Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 16 (17): 2252-63, 2002.[PUBMED Abstract]

Taniguchi K, Roberts LR, Aderca IN, et al.: Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21 (31): 4863-71, 2002.[PUBMED Abstract]

Wei SH, Chen CM, Strathdee G, et al.: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8 (7): 2246-52, 2002.[PUBMED Abstract]

Zhai Y, Wu R, Schwartz DR, et al.: Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 160 (4): 1229-38, 2002.[PUBMED Abstract]

Ahluwalia A, Yan P, Hurteau JA, et al.: DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 82 (2): 261-8, 2001.[PUBMED Abstract]

Giordano TJ, Shedden KA, Schwartz DR, et al.: Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 159 (4): 1231-8, 2001.[PUBMED Abstract]

Nees M, Geoghegan JM, Hyman T, et al.: Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75 (9): 4283-96, 2001.[PUBMED Abstract]

Shi W, Arnold GS, Bartlett JS: Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12 (14): 1697-711, 2001.[PUBMED Abstract]

Smith SA, Richards WE, Caito K, et al.: BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol 83 (3): 586-92, 2001.[PUBMED Abstract]

Smith SA, Richards WE, Caito K, et al.: BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol 83 (3): 586-92, 2001.[PUBMED Abstract]

Welsh JB, Zarrinkar PP, Sapinoso LM, et al.: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98 (3): 1176-81, 2001.[PUBMED Abstract]

Wu R, Zhai Y, Fearon ER, et al.: Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61 (22): 8247-55, 2001.[PUBMED Abstract]

Best CJ, Gillespie JW, Englert CR, et al.: New approaches to molecular profiling of tissue samples. Anal Cell Pathol 20 (1): 1-6, 2000.[PUBMED Abstract]

Blumenthal RD, Samoszuk M, Taylor AP, et al.: Degranulating eosinophils in human endometriosis. Am J Pathol 156 (5): 1581-8, 2000.[PUBMED Abstract]

Emmert-Buck MR, Strausberg RL, Krizman DB, et al.: Molecular profiling of clinical tissue specimens: feasibility and applications. Am J Pathol 156 (4): 1109-15, 2000.[PUBMED Abstract]

Gaiotti D, Chung J, Iglesias M, et al.: Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog 27 (2): 97-109, 2000.[PUBMED Abstract]

Gan L, Lee I, Smith R, et al.: Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257 (1): 119-30, 2000.[PUBMED Abstract]

Hu JF, Ulaner GA, Oruganti H, et al.: Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens. Biochim Biophys Acta 1491 (1-3): 49-56, 2000.[PUBMED Abstract]

Nees M, Geoghegan JM, Munson P, et al.: Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res 60 (15): 4289-98, 2000.[PUBMED Abstract]

Ross JA, Radloff GA, Davies SM: H19 and IGF-2 allele-specific expression in hepatoblastoma. Br J Cancer 82 (4): 753-6, 2000.[PUBMED Abstract]

Strausberg RL, Buetow KH, Emmert-Buck MR, et al.: The cancer genome anatomy project: building an annotated gene index. Trends Genet 16 (3): 103-6, 2000.[PUBMED Abstract]

Underwood LJ, Shigemasa K, Tanimoto H, et al.: Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim Biophys Acta 1502 (3): 337-50, 2000.[PUBMED Abstract]

Brown MR, Chuaqui R, Vocke CD, et al.: Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Gynecol Oncol 74 (1): 98-102, 1999.[PUBMED Abstract]

Hanna EA, Umhauer S, Roshong SL, et al.: Gap junctional intercellular communication and connexin43 expression in human ovarian surface epithelial cells and ovarian carcinomas in vivo and in vitro. Carcinogenesis 20 (7): 1369-73, 1999.[PUBMED Abstract]

Krizman DB, Wagner L, Lash A, et al.: The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression. Neoplasia 1 (2): 101-6, 1999.[PUBMED Abstract]

Ross JA, Schmidt PT, Perentesis JP, et al.: Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. Cancer 85 (6): 1389-94, 1999.[PUBMED Abstract]

Underwood LJ, Tanimoto H, Wang Y, et al.: Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59 (17): 4435-9, 1999.[PUBMED Abstract]

Wang K, Gan L, Jeffery E, et al.: Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229 (1-2): 101-8, 1999.[PUBMED Abstract]

Wu M, Gunning W, Ratnam M: Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8 (9): 775-82, 1999.[PUBMED Abstract]

DiPaolo JA, Woodworth CD, Coutlée F, et al.: Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer 76 (6): 865-71, 1998.[PUBMED Abstract]

Malins DC, Polissar NL, Schaefer S, et al.: A unified theory of carcinogenesis based on order-disorder transitions in DNA structure as studied in the human ovary and breast. Proc Natl Acad Sci U S A 95 (13): 7637-42, 1998.[PUBMED Abstract]

Peterson LA, Brown MR, Carlisle AJ, et al.: An improved method for construction of directionally cloned cDNA libraries from microdissected cells. Cancer Res 58 (23): 5326-8, 1998.[PUBMED Abstract]

Rakowicz-Szulczynska EM, Jackson B, Snyder W: Prostate, breast and gynecological cancer markers RAK with homology to HIV-1. Cancer Lett 124 (2): 213-23, 1998.[PUBMED Abstract]

Riopel MA, Spellerberg A, Griffin CA, et al.: Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res 58 (14): 3105-10, 1998.[PUBMED Abstract]

Rubin SC, Blackwood MA, Bandera C, et al.: BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178 (4): 670-7, 1998.[PUBMED Abstract]

Bandera CA, Takahashi H, Behbakht K, et al.: Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma. Cancer Res 57 (3): 513-5, 1997.[PUBMED Abstract]

Brooks PC, Klemke RL, Schon S, et al.: Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 99 (6): 1390-8, 1997.[PUBMED Abstract]

Courtois SJ, Woodworth CD, Degreef H, et al.: Early ultraviolet B-induced G1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. Exp Cell Res 233 (1): 135-44, 1997.[PUBMED Abstract]

Ilekis JV, Connor JP, Prins GS, et al.: Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66 (2): 250-4, 1997.[PUBMED Abstract]

Ilekis JV, Gariti J, Niederberger C, et al.: Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol 65 (1): 36-41, 1997.[PUBMED Abstract]

Lei XD, Woodworth CD, Johnen G, et al.: Expression of 4alpha-carbinolamine dehydratase in human epidermal keratinocytes. Biochem Biophys Res Commun 238 (2): 556-9, 1997.[PUBMED Abstract]

Schweinfest CW, Graber MW, Chapman JM, et al.: CaSm: an Sm-like protein that contributes to the transformed state in cancer cells. Cancer Res 57 (14): 2961-5, 1997.[PUBMED Abstract]

DiPaolo JA, Popescu NC, Woodworth CD, et al.: Papillomaviruses and potential copathogens. Toxicol Lett 88 (1-3): 1-7, 1996.[PUBMED Abstract]

Goff BA, Shy K, Greer BE, et al.: Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol 17 (6): 487-92, 1996.[PUBMED Abstract]

Holt JT, Thompson ME, Szabo C, et al.: Growth retardation and tumour inhibition by BRCA1. Nat Genet 12 (3): 298-302, 1996.[PUBMED Abstract]

Jensen RA, Thompson ME, Jetton TL, et al.: BRCA1 is secreted and exhibits properties of a granin. Nat Genet 12 (3): 303-8, 1996.[PUBMED Abstract]

Kremer R, Woodworth CD, Goltzman D: Expression and action of parathyroid hormone-related peptide in human cervical epithelial cells. Am J Physiol 271 (1 Pt 1): C164-71, 1996.[PUBMED Abstract]

Lancaster JM, Cochran CJ, Brownlee HA, et al.: Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. J Natl Cancer Inst 88 (8): 552-4, 1996.[PUBMED Abstract]

Phillips NJ, Zeigler MR, Deaven LL: A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett 102 (1-2): 85-90, 1996.[PUBMED Abstract]

Rubin SC, Benjamin I, Behbakht K, et al.: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335 (19): 1413-6, 1996.[PUBMED Abstract]

Schultz DC, Vanderveer L, Berman DB, et al.: Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56 (9): 1997-2002, 1996.[PUBMED Abstract]

Scoccia B, Lee YM, Niederberger C, et al.: Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Investig 5 (3): 161-5, 1998 May-Jun.[PUBMED Abstract]

Shigemasa K, Tanimoto H, Parham GP, et al.: Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 6 (2): 102-8, 1999 Mar-Apr.[PUBMED Abstract]

Thai TH, Du F, Tsan JT, et al.: Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7 (2): 195-202, 1998.[PUBMED Abstract]

Simpson S, Woodworth CD, DiPaolo JA: Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Oncogene 14 (18): 2149-57, 1997.[PUBMED Abstract]

Tanimoto H, Mehta KD, Parmley TH, et al.: Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation. Gynecol Oncol 66 (2): 308-12, 1997.[PUBMED Abstract]

Tanimoto H, Yan Y, Clarke J, et al.: Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57 (14): 2884-7, 1997.[PUBMED Abstract]

Sicinski P, Donaher JL, Geng Y, et al.: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384 (6608): 470-4, 1996.[PUBMED Abstract]

Steller MA, Delgado CH, Bartels CJ, et al.: Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 56 (8): 1761-5, 1996.[PUBMED Abstract]

Takahashi H, Chiu HC, Bandera CA, et al.: Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56 (12): 2738-41, 1996.[PUBMED Abstract]

Tripathi PK, Chatterjee SK: Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Cancer Invest 14 (6): 518-26, 1996.[PUBMED Abstract]

Woodworth CD, Chung J, McMullin E, et al.: Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation. Cell Growth Differ 7 (6): 811-20, 1996.[PUBMED Abstract]

Alvarez-Salas LM, Velazquez A, Lopez-Bayghen E, et al.: Transcriptional repression in normal human keratinocytes by wild-type and mutant p53. Cancer Lett 91 (1): 85-92, 1995.[PUBMED Abstract]

Bukovsky A, Caudle MR, Keenan JA, et al.: Expression of cell cycle regulatory proteins (p53, pRb) in the human female genital tract. J Assist Reprod Genet 12 (2): 123-31, 1995.[PUBMED Abstract]

Bukovský A, Caudle MR, Keenan JA, et al.: Quantitative evaluation of the cell cycle-related retinoblastoma protein and localization of Thy-1 differentiation protein and macrophages during follicular development and atresia, and in human corpora lutea. Biol Reprod 52 (4): 776-92, 1995.[PUBMED Abstract]

Bukovský A, Caudle MR, Keenan JA, et al.: Is corpus luteum regression an immune-mediated event? Localization of immune system components and luteinizing hormone receptor in human corpora lutea. Biol Reprod 53 (6): 1373-84, 1995.[PUBMED Abstract]

Bukovský A, Keenan JA, Caudle MR, et al.: Immunohistochemical studies of the adult human ovary: possible contribution of immune and epithelial factors to folliculogenesis. Am J Reprod Immunol 33 (4): 323-40, 1995.[PUBMED Abstract]

Cameron MR, Caudle MR, Sullivan WR Jr, et al.: The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells. Oncol Res 7 (3-4): 145-56, 1995.[PUBMED Abstract]

Gallion HH, Pieretti M, DePriest PD, et al.: The molecular basis of ovarian cancer. Cancer 76 (10 Suppl): 1992-7, 1995.[PUBMED Abstract]

Gerald WL, Rosai J, Ladanyi M: Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci U S A 92 (4): 1028-32, 1995.[PUBMED Abstract]

Gordon AW, Pegues JC, Johnson GR, et al.: mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett 89 (1): 63-71, 1995.[PUBMED Abstract]

Iglesias M, Plowman GD, Woodworth CD: Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol 146 (4): 944-52, 1995.[PUBMED Abstract]

Pieretti M, Cavalieri C, Conway PS, et al.: Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64 (6): 434-40, 1995.[PUBMED Abstract]

Pieretti M, Powell DE, Gallion HH, et al.: Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 26 (4): 393-7, 1995.[PUBMED Abstract]

Pieretti M, Powell DE, Gallion HH, et al.: Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer. Hum Pathol 26 (4): 398-401, 1995.[PUBMED Abstract]

Schultz DC, Vanderveer L, Buetow KH, et al.: Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55 (10): 2150-7, 1995.[PUBMED Abstract]

Takahashi H, Behbakht K, McGovern PE, et al.: Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55 (14): 2998-3002, 1995.[PUBMED Abstract]

Woodworth CD, McMullin E, Iglesias M, et al.: Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A 92 (7): 2840-4, 1995.[PUBMED Abstract]

Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (5158): 569-71, 1994.[PUBMED Abstract]

Harris JD, Hibler DW, Fontenot GK, et al.: Cloning and characterization of zona pellucida genes and cDNAs from a variety of mammalian species: the ZPA, ZPB and ZPC gene families. DNA Seq 4 (6): 361-93, 1994.[PUBMED Abstract]

Ladanyi M, Gerald W: Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 54 (11): 2837-40, 1994.[PUBMED Abstract]

Orth K, Hung J, Gazdar A, et al.: Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A 91 (20): 9495-9, 1994.[PUBMED Abstract]

Orth K, Hung J, Gazdar A, et al.: Ovarian tumors display persistent microsatellite instability caused by mutation in the mismatch repair gene hMSH-2. Cold Spring Harb Symp Quant Biol 59: 349-56, 1994.[PUBMED Abstract]

Ross JF, Chaudhuri PK, Ratnam M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73 (9): 2432-43, 1994.[PUBMED Abstract]

Rowell S, Newman B, Boyd J, et al.: Inherited predisposition to breast and ovarian cancer. Am J Hum Genet 55 (5): 861-5, 1994.[PUBMED Abstract]

Shen F, Ross JF, Wang X, et al.: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 33 (5): 1209-15, 1994.[PUBMED Abstract]

Stromberg K, Johnson GR, O'Connor DM, et al.: Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol 13 (4): 342-7, 1994.[PUBMED Abstract]

Tanimoto H, Underwood LJ, Shigemasa K, et al.: The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 20 (2): 88-98, 1999 Mar-Apr.[PUBMED Abstract]

Varricchio F, Stromberg K: An albumin-like protein is the major secretory protein of ovarian epithelial cells in vivo and in vitro. Int J Gynecol Cancer 4 (5): 328-332, 1994.[PUBMED Abstract]

Coppes MJ, Ye Y, Rackley R, et al.: Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res 53 (12): 2712-4, 1993.[PUBMED Abstract]

Woodworth CD, Simpson S: Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol 142 (5): 1544-55, 1993.[PUBMED Abstract]

Woodworth CD, Wang H, Simpson S, et al.: Overexpression of wild-type p53 alters growth and differentiation of normal human keratinocytes but not human papillomavirus-expressing cell lines. Cell Growth Differ 4 (5): 367-76, 1993.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Michael Cibull, MD, Protocol chair		Ph: 859-257-5357

U.S.A.
Arkansas
	Little Rock
	Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
		Clinical Trial Office - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences	Ph:  501-686-8274
California
	Burbank
	Providence Saint Joseph Medical Center - Burbank
		Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank	Ph:  818-847-3220
	Long Beach
	Todd Cancer Institute at Long Beach Memorial Medical Center
		Krishnansu Tewari	Ph:  562-933-0900
	Los Angeles
	Jonsson Comprehensive Cancer Center at UCLA
		Clinical Trials Office - Jonsson Comprehensive Cancer Center at UCLA	Ph:  888-798-0719
	Sacramento
	University of California Davis Cancer Center
		Clinical Trials Office - University of California Davis Cancer Center	Ph:  916-734-3089
	San Francisco
	UCSF Helen Diller Family Comprehensive Cancer Center
		Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center	Ph:  877-827-3222
	Sylmar
	Olive View - UCLA Medical Center Foundation
		Christine Holschneider, MD	Ph:  310-206-5161
Colorado
	Aurora
	Colorado Gynecologic Oncology Group, PC
		Susan Davidson, MD	Ph:  303-315-7897
Connecticut
	Hartford
	Helen and Harry Gray Cancer Center at Hartford Hospital
		Clinical Trials Office - Helen and Harry Gray Cancer Center	Ph:  860-545-5363
	New Britain
	George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
		Clinical Trials Office - George Bray Cancer Center	Ph:  860-224-5660
	New Haven
	Yale Cancer Center
		Clinical Trials Office - Yale Cancer Center	Ph:  203-785-5702
Florida
	Fort Myers
	Florida Gynecologic Oncology - Fort Myers
		Edward Grendys, MD	Ph:  239-992-0077
	Jupiter
	Ella Milbank Foshay Cancer Center at Jupiter Medical Center
		Clinical Trials Office - Ella Milbank Foshay Cancer Center	Ph:  561-745-5768
Georgia
	Augusta
	MBCCOP - Medical College of Georgia Cancer Center
		Sharad Ghamande, MD	Ph:  706-721-3992
	Gainesville
	Northeast Georgia Medical Center
		Andrew Green	Ph:  770-535-3553
	Savannah
	Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
		Clinical Trials Office - Curtis and Elizabeth Anderson Cancer Institute	Ph:  912-350-8568
Illinois
	Chicago
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Ph:  312-695-1301
			Email: cancer@northwestern.edu
	University of Illinois Cancer Center
		Clinical Trial Office - University of Illinois Cancer Center	Ph:  312-355-3046
	Hinsdale
	Hinsdale Hematology Oncology Associates
		Sudarshan Sharma, MD	Ph:  630-856-6757
	Maywood
	Cardinal Bernardin Cancer Center at Loyola University Medical Center
		Clinical Trials Office - Cardinal Bernardin Cancer Center	Ph:  708-226-4357
	Springfield
	Regional Cancer Center at Memorial Medical Center
		Clinical Trials Office - Regional Cancer Center at Memorial Medical Center	Ph:  217-788-4233
Indiana
	Indianapolis
	Indiana University Melvin and Bren Simon Cancer Center
		Clinical Trials Office - Indiana University Cancer Center	Ph:  317-274-2552
Iowa
	Iowa City
	Holden Comprehensive Cancer Center at University of Iowa
		Cancer Information Service	Ph:  800-237-1225
Kentucky
	Edgewood
	Esther Marie Hatton Cancer Care Center at St. Elizabeth Medical Center
		Jack Basil, MD	Ph:  513-872-3401
	Lexington
	Lucille P. Markey Cancer Center at University of Kentucky
		Clinical Trials Office - Markey Cancer Center at University of Kentucky Chandler Medical Center	Ph:  859-257-3379
	Louisville
	Louisville Oncology at Norton Cancer Institute - Louisville
		Clinical Trials Office - Louisville Oncology	Ph:  502-629-2500
Louisiana
	Baton Rouge
	Woman's Hospital
		Giles Fort, MD	Ph:  225-358-1071
Maine
	Portland
	Maine Medical Center - Bramhall Campus
		Clinical Trials Office - Maine Medical Center - Bramhall Campus	Ph:  207-885-7565
Maryland
	Baltimore
	Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
		Clinical Trials Office - Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center	Ph:  443-777-7364
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
		Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Center at John Hopkins	Ph:  410-955-8804
			Email: jhcccro@jhmi.edu
Massachusetts
	Worcester
	UMASS Memorial Cancer Center - University Campus
		Susan Zweizig, MD	Ph:  508-334-1160
Michigan
	Ann Arbor
	University of Michigan Comprehensive Cancer Center
		Clinical Trials Office - University of Michigan Comprehensive Cancer Center	Ph:  800-865-1125
	Grand Rapids
	Gynecologic Oncology of West Michigan
		Gordon Downey, MD	Ph:  616-957-3398
Mississippi
	Jackson
	St. Dominic Cancer Center
		Donald Seago	Ph:  601-200-3070
	University of Mississippi Cancer Clinic
		James Thigpen, MD	Ph:  601-984-5590
Missouri
	Columbia
	Ellis Fischel Cancer Center at University of Missouri - Columbia
		Clinical Trial Office - Ellis Fischel Cancer Center	Ph:  573-882-7440
	Saint Louis
	Saint Louis University Cancer Center
		Clinical Trials Office - Saint Louis University Cancer Center	Ph:  314-977-4440
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		David Mutch, MD	Ph:  314-362-3181
Nebraska
	Omaha
	Methodist Estabrook Cancer Center
		Peter Morris, MD	Ph:  402-354-5250
Nevada
	Las Vegas
	Women's Cancer Center - Lake Mead
		Nick Spirtos, MD	Ph:  408-866-3843
New Hampshire
	Lebanon
	Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
		Clinical Trials Office - Norris Cotton Cancer Center	Ph:  603-650-7609
			Email: cancerhelp@dartmouth.edu
New Jersey
	Morristown
	Carol G. Simon Cancer Center at Morristown Memorial Hospital
		Paul Heller, MD	Ph:  973-971-5900
	Neptune
	Jersey Shore Cancer Center at Jersey Shore University Medical Center
		Henry Sprance, MD, PhD	Ph:  732-776-4128
	Summit
	Overlook Hospital
		Paul Heller, MD	Ph:  973-971-5900
New Mexico
	Albuquerque
	University of New Mexico Cancer Center
		Clinical Trials Office - University of New Mexico Cancer Center	Ph:  505-272-6972
New York
	New York
	Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
		Clinical Trials Office - Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center	Ph:  212-305-8615
	Mount Sinai Medical Center
		Nimesh Nagarsheth	Ph:  212-241-6500
	Stony Brook
	Stony Brook University Cancer Center
		Clinical Trials Office - Stony Brook University Cancer Center	Ph:  800-862-2215
North Carolina
	Chapel Hill
	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
		Clinical Trials Office - Lineberger Comprehensive Cancer Center	Ph:  877-668-0683; 919-966-4432
	Pinehurst
	FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
		Clinical Trials Office - FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center	Ph:  910-715-2200
	Winston-Salem
	Wake Forest University Comprehensive Cancer Center
		Clinical Trials Office - Wake Forest University Comprehensive Cancer Center	Ph:  336-713-6771
Ohio
	Akron
	McDowell Cancer Center at Akron General Medical Center
		Eric Jenison, MD	Ph:  330-344-6041
	Cincinnati
	Charles M. Barrett Cancer Center at University Hospital
		William Richards	Ph:  806-796-1317
	Good Samaritan Hospital Cancer Treatment Center
		Jack Basil, MD	Ph:  513-872-3401
	Cleveland
	Case Comprehensive Cancer Center
		Clinical Trials Office - Case Comprehensive Cancer Center	Ph:  800-641-2422
	Cleveland Clinic Cancer Center at Fairview Hospital
		Clinical Trials Office - Cleveland Clinic Cancer Center at Fairview Hospital	Ph:  216-476-9362
	Cleveland Clinic Taussig Cancer Center
		Clinical Trials Office - Cleveland Clinic Taussig Cancer Center	Ph:  866-223-8100
	Columbus
	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
		Ohio State University Cancer Clinical Trial Matching Service	Ph:  866-627-7616
			Email: osu@emergingmed.com
	Riverside Methodist Hospital Cancer Care
		Clinical Trials Office - Riverside Methodist Hospital Cancer Care	Ph:  614-566-4475
	Dayton
	David L. Rike Cancer Center at Miami Valley Hospital
		Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital	Ph:  937-208-2079
	Mayfield Heights
	Hillcrest Cancer Center at Hillcrest Hospital
		Peter Rose, MD	Ph:  216-444-1712
	Mentor
	Lake/University Ireland Cancer Center
		Steven Waggoner, MD	Ph:  216-844-5011
Oklahoma
	Oklahoma City
	Oklahoma University Cancer Institute
		Robert Mannel, MD	Ph:  405-271-8787
	Tulsa
	Cancer Care Associates - Saint Francis Campus
		Robert Mannel, MD	Ph:  405-271-8787
Oregon
	Portland
	Legacy Good Samaritan Hospital & Comprehensive Cancer Center
		Clinical Trials Office - Legacy Good Samaritan Hospital & Comprehensive Cancer Center	Ph:  503-413-1742
	Northwest Cancer Specialists at Rose Quarter Cancer Center
		William Winter, III	Ph:  503-228-6509
Pennsylvania
	Abington
	Rosenfeld Cancer Center at Abington Memorial Hospital
		Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital	Ph:  215-481-2402
	Allentown
	Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
		Richard Boulay, MD	Ph:  610-402-3650
	Bethlehem
	St. Luke's Cancer Network at St. Luke's Hospital
		David Silver, MD	Ph:  702-427-4999
	Philadelphia
	Abramson Cancer Center of the University of Pennsylvania
		Clinical Trials Office - Abramson Cancer Center of the University of Pennsylvania	Ph:  800-474-9892
	Fox Chase Cancer Center - Philadelphia
		Clinical Trials Office - Fox Chase Cancer Center - Philadelphia	Ph:  215-728-4790
	Fox Chase Cancer Center CCOP Research Base
		Clinical Trials Office - Fox Chase Cancer Center CCOP Research Base	Ph:  215-728-2983
	Joan Karnell Cancer Center at Pennsylvania Hospital
		Patricia Ford, MD	Ph:  215-829-6088
	Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
		Clinical Trials Office - Kimmel Cancer Center at Thomas Jefferson University - Philadelphia	Ph:  215-955-6084
	Pittsburgh
	UPMC Cancer Center at Magee-Womens Hospital
		Clinical Trials Office - UPMC Cancer Center at Magee-Womens Hospital	Ph:  412-647-2811
Rhode Island
	Providence
	Women and Infants Hospital of Rhode Island
		Clinical Trials Office - Women and Infants Hospital of Rhode Island	Ph:  401-274-1122
South Carolina
	Charleston
	Hollings Cancer Center at Medical University of South Carolina
		Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina	Ph:  843-792-9321
South Dakota
	Rapid City
	Black Hills Obstetrics & Gynecology LLP
		Helen Frederickson, MD	Ph:  605-343-9224
	Sioux Falls
	Sanford Cancer Center at Sanford USD Medical Center
		Clinical Trials Office - Sanford Cancer Center	Ph:  605-328-1367
Tennessee
	Chattanooga
	Chattanooga's Program in Women's Oncology
		Stephen DePasquale	Ph:  423-266-3636
	Knoxville
	Hall and Martin, M.Ds., PC
		David Martin	Ph:  865-971-4992
	Nashville
	MBCCOP - Meharry Medical College - Nashville
		Steven Wolff, MD	Ph:  615-327-6277
	Vanderbilt-Ingram Cancer Center
		Clinical Trials Office - Vanderbilt-Ingram Cancer Center	Ph:  800-811-8480
Texas
	Dallas
	Parkland Memorial Hospital
		David Miller, MD	Ph:  214-648-3026
	Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
		Clinical Trials Office - Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas	Ph:  866-460-4673; 214-648-7097
	UT Southwestern University Hospital - Zale Lipshy
		David Miller, MD	Ph:  214-648-3026
	Fort Sam Houston
	Brooke Army Medical Center
		Clinical Trials Office - Brooke Army Medical Center	Ph:  210-916-4837
	Galveston
	University of Texas Medical Branch
		Clinical Trials Office - University of Texas Medical Branch	Ph:  409-772-1950
	Houston
	Methodist Hospital
		Tri Dinh	Ph:  713-441-1010
	Lackland AFB
	Wilford Hall Medical Center
		Charles Leath, III	Ph:  210-292-7100
	Temple
	CCOP - Scott and White Hospital
		Charles Capen, MD	Ph:  254-724-2576
Vermont
	Burlington
	Fletcher Allen Health Care - University Health Center Campus
		Clinical Trials Office - Fletcher Allen Health Care	Ph:  802-656-8990
Virginia
	Norfolk
	Virginia Oncology Associates - Lake Wright
		Robert Squatrito, MD	Ph:  757-466-1466
Washington
	Seattle
	Fred Hutchinson Cancer Research Center
		Benjamin Greer, MD	Ph:  206-685-2463
	University Cancer Center at University of Washington Medical Center
		Clinical Trials Office - University Cancer Center at University of Washington Medical Center	Ph:  206-616-8289
Wisconsin
	Chippewa Falls
	Marshfield Clinic - Chippewa Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Eau Claire
	Marshfield Clinic Cancer Care at Regional Cancer Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Ladysmith
	Marshfield Clinic - Ladysmith Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Madison
	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
		Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center	Ph:  608-262-5223
	Marshfield
	Marshfield Clinic - Marshfield Center
		Clinical Trials Office - Marshfield Clinic - Marshfield Center	Ph:  800-782-1581 ext. 94457
	Saint Joseph's Hospital
		Stuart Tipping, MD	Ph:  715-389-7549
	Milwaukee
	Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
		Clinical Trials Office - Vince Lombardi Cancer Clinic	Ph:  414-649-5717
	Minocqua
	Marshfield Clinic - Lakeland Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Rhinelander
	Ministry Medical Group at Saint Mary's Hospital
		Stuart Tipping, MD	Ph:  715-389-7549
	Rice Lake
	Marshfield Clinic - Indianhead Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Stevens Point
	Saint Michael's Hospital Cancer Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Wausau
	Marshfield Clinic - Wausau Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Weston
	Diagnostic and Treatment Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Marshfield Clinic - Weston Center
		Stuart Tipping, MD	Ph:  715-389-7549
	Wisconsin Rapids
	Marshfield Clinic - Wisconsin Rapids Center
		Stuart Tipping, MD	Ph:  715-389-7549

Registry Information
Official Title		Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
Trial Start Date		1992-06-16
Registered in ClinicalTrials.gov		NCT00897442
Date Submitted to PDQ		1994-11-16
Information Last Verified		2009-11-26
NCI Grant/Contract Number		U10-CA27469

Back to Top